Companies › Gracell Biotechnologies (Shanghai)
1 active drug program in 3 registered trials: 3 Phase 1; Immunology, Metabolic and endocrine, Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GC012F BCMA/CD19 dual CAR-T cell therapy | TNFRSF17, CD19, BCMA | Phase 1 | Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL Amyloidosis | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06235229 | GC012F | Phase 1 | Multiple Myeloma | Oncology | Mar 2026 |
| NCT06530849 | GC012F | Phase 1 | Refractory Systemic Lupus Erythematosus | Immunology | Feb 2027 |
| NCT07250269 | GC012F | Phase 1 | Relapsed/Refractory AL Amyloidosis | Metabolic and endocrine | Nov 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.